Severity and treatment need

Allergic rhinitis is underestimated and undertreated

74% of perennial allergic rhinitis sufferers have moderate to severe symptoms (n=392).¹

2 in 3 patients are still uncontrolled, despite having multiple treatments.²

13% of these uncontrolled patients have visited their doctor 5 or more times in the previous year, due to their allergic rhinitis.²

PHARMACOTHERAPY EFFECTS ON INDIVIDUAL RHINITIS SYMPTOMS

	Sneezing	Rhinorrhea	Nasal obstruction	Nasal itch	Eye symptoms
H1-antihistamines
Oral	++	++	+	+++	++
Intranasal	++	++	+	++	0
Eye drops	0	0	0	0	+++
Corticosteroids
Intranasal	+++	+++	++	++	++
Chromones
Intranasal	+	+	+	+	0
Eye drops	0	0	0	0	++
Decongestants
Intranasal	0	0	++++	0	0
Oral	0	0	+	0	0
Anti-cholinergics	0	++	0	0	0
Anti-leukotrienes	0	+	++	0	++
Intranasal steroids and intranasal antihistamine (Dymista^®)	+++	+++	+++	+++	+++

Adapted from Scadding GK, et al. 2017.³

References

Canonica GW, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62(Suppl. 85): 17-25.
Klimek L, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015; 36(1): 40-47.
Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856-889.

DYM-2023-0848 November 2023

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?

YES

Viatris Connect is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW

Adverse events and device failures should be reported

Please report suspected adverse drug reactions (ADRs) and device failures to the MHRA through the Yellow Card scheme. You can report via:

• the Yellow Card website www.mhra.gov.uk/yellowcard
• the free Yellow Card app available from the Apple App Store or Google Play Store
• some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) for healthcare professionals

Alternatively, you can report suspected adverse drug reactions and device failures to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible. By reporting adverse drug reactions and device failures, you can help provide more information on the safety of this medicine.

You can also report directly to the manufacturer at pv.uk@viatris.com

This website is owned and managed by Viatris. For more information visit viatris.co.uk

This is a promotional site intended for UK healthcare professionals. If you're a patient who has been prescribed Dymista^® (azelastine hydrochloride/fluticasone propionate), please click here.

Dymista^® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)